The milestones in xenotransplantation – cross-species transplants – rely on cutting-edge biotechnologies, including the use ...

Editor's Note: pharmaphorum is an editorially independent publication owned by EVERSANA.

The discovery by the UK Health Security Agency (UKHSA) raises the possibility that viral diseases that are known to be ...

Ionis' antisense therapy Zanvastro has been approved by the FDA for Alexander disease (AxD), throwing a lifeline to people ...

Interim data from the 393-patient phase 3 CERVINO trial of etentamig (ABBV-383), a bispecific CD3 and BCMA-directed TCE, ...

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio companies, Istesso, had failed a phase 2b trial. The early-stage investor in life ...

Denmark's Netcompany has been awarded a five-year contract from NHS England, worth more than £215 million, to build the ...

PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027 ...

The new acquisition is Lilly's ninth since the start of the year, coming just a few weeks after it agreed to buy psychedelic ...

The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, ...

The US FDA issued similar warning letters to five different online peptide vendors on 24th August, giving the companies 15 ...

Shares in China's Hutchmed surged today after GSK paid $110 million upfront for rights to a preclinical-stage KRAS and EGFR-targeted drug with potential in colorectal, pancreatic, and lung cancer.